Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
75 participants
INTERVENTIONAL
2019-06-01
2023-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study involves randomization. There is a 50 percent chance (like a flip of the coin) that you will be randomized to attend meditation sessions during treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Guided Meditation During Radiation Therapy for Brain Tumors
NCT06165653
Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy
NCT02170350
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
NCT07166042
Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy
NCT02067351
Effects of a Second-generation Mindfulness-based Intervention on Quality of Life, Pain Management, and Psycho-spiritual Wellbeing in Cancer Patients: A Randomised Controlled Trial
NCT06695234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
Standard of Care
Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
Meditation
Meditation
Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meditation
Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
Standard of Care
Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prescribed a course of at least 15 daily fractions of RT for curative intent of any malignancy
* Willing to attend MBI sessions weekly during RT
* Able to transport themselves to scheduled MBI sessions in the DAHLC
* Able to complete questionnaire(s) by themselves
* Native English speaker (MBI sessions, videos, and QOL questionnaires are only available in English)
* ECOG Performance Status 0-2
Exclusion Criteria
* Unable or unwilling to attend required MBI sessions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kimberly S. Corbin
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kimberly S. Corbin, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-02757
Identifier Type: REGISTRY
Identifier Source: secondary_id
18-004546
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.